A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1 Meeting Abstract
| Authors: | Sangro, B.; Kudo, M.; Qin, S.; Ren, Z.; Chan, S.; Joseph, E.; Arai, Y.; Mann, H.; Morgan, S.; Cohen, G.; Lencioni, R. |
| Abstract Title: | A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1 |
| Meeting Title: | ESMO 22nd World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2020 Jul 1-4 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-07-01 |
| Start Page: | S202 |
| End Page: | S203 |
| Language: | English |
| ACCESSION: | WOS:000558722000348 |
| DOI: | 10.1016/j.annonc.2020.04.429 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P-347 -- Source: Wos |
